Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

CMS Final Rule Cuts Cardiology Reimbursement by 1% in 2023

News Daily News

CMS Final Rule for 2023 Physician Fee Schedule Gets Mixed Reactions

Yael L. Maxwell

November 02, 2022

News Conference News TCT 2022

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

Shelley Wood

September 18, 2022

News Daily News

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Todd Neale

September 15, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News EuroPCR 2022

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Michael O'Riordan

May 19, 2022

Presentation ACC 2022

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Presenter: Milind Y Desai

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

News Features

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

Shelley Wood

March 14, 2022

Video

» Interview

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

May 4, 2022

Video

» Interview

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

April 3, 2022

Advertisement

CMS Final Rule for 2023 Physician Fee Schedule Gets Mixed Reactions

Pulmonary Artery Denervation in Idiopathic PAH Ups 6-Minute Walk Test

Pacemaker Doesn’t Harm Outcomes of Alcohol Septal Ablation for Obstructive HCM

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

MitraClip Helps for Atrial Functional MR: MITRA-TUNE

Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Aortic Valve Replacement: What’s on the Wish List for Future Devices?

"Myosin Inhibition to Defer Surgical Myectomy or Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Results of the VALOR Trial"

ACC 2022: VALOR-HCM - Mavacamten As An Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content